Overview

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Status:
Completed
Trial end date:
2010-11-04
Target enrollment:
0
Participant gender:
All
Summary
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Muslim men and women with type 2 diabetes

- Participants who intend to fast during the month of Ramadan

- Participants who have been on a stable dose of sulfonylurea for at least three months

Exclusion Criteria:

- Participants with type 1 diabetes mellitus

- Pregnant or breast feeding women

- Participants with hypersensitivity or contraindication to dipeptidyl peptidase (DPP-4)
treatment

- Participants on insulin

- Participants on any class of oral diabetic therapy other than sulfonylurea or
metformin